Avivagen Announces Stock Option Pool Increase
14 Febrero 2014 - 7:00AM
Access Wire
OTTAWA, ONTARIO, February 14, 2014
- Avivagen Inc. (TSXV:VIV), a wellness
company developing and delivering products that support and enhance
the health and quality of life for animals and the people who care
for them, today announced that its board of directors has approved
amendments to its stock option plan.
The amendments, among other things,
increase the pool of shares available for issuance on exercise of
options issued pursuant to the plan, from 10,751,051 to 15,907,934.
This represents approximately 9.5% of the 167,451,943 issued and
outstanding shares of Avivagen.
The other changes to the plan were made to reflect
changes to the TSX Venture Exchange policies on stock option plans
that have come into effect since the last amendment to Avivagen's
option plan. None of the incremental pool has been awarded and the
issuance of any new options requires approval by the Board of
Directors of Avivagen.
The purpose of the option plan is to
provide equity incentive compensation to employees, consultants,
directors, and officers. A copy of the amended plan will be made
available at www.sedar.com.
About Avivagen Inc.
Avivagen Inc. is a publicly-listed life sciences
company trading on the TSX Venture Exchange under the ticker symbol
"VIV". The Company's goal is to develop and deliver
scientifically-proven solutions that can truly benefit companion
and production animals by employing natural mechanisms for
maintaining good health. Avivagen's targeted markets include Pet
Wellness and Livestock Productivity.
The company has sites located in
partnership facilities of the National Research Council of Canada
(NRC) - in Ottawa, Ontario and Charlottetown, Prince Edward
Island. More information can be found
at www.avivagen.com.
About OxC-beta
Avivagen's proprietary and patent-protected technology
is based on its discoveries concerning carotenoid antioxidants. The
novel natural compounds discovered by Avivagen support the body's
own systems to maintain and enhance health, particularly by
supporting immune function. Avivagen's commercial-stage application
of its technology is Fully-Oxidized beta-Carotene (OxC-beta).
OxC-beta compounds occur naturally as carotenoid oxidation products
in vegetation, but in minute amounts. They have been developed to
support the health of companion animals and for use in the global
food animal market.
Research results indicate OxC-beta supports innate
immune function, which can help maintain good health. In pets,
OxC-beta supports overall vitality and energy, mobility and joint
function, skin, coat and gut. Results observed in food animals have
included healthier growth, better utilization of feed and decreased
mortality. In food animals, it is intended that use of OxC-beta
avoids the feeding of antibiotics.
The commercial products of Avivagen are
Oximunol(TM) Chewables, OxC-beta for livestock and Vivamune(TM)
Health Chews.
About Vivamune(TM) Health Chews - For
dogs and cats
Vivamune(TM) Health Chews, containing
Avivagen's proprietary active ingredients, are
scientifically-formulated chews for dogs and cats. Vivamune(TM)
Health Chews work with a pet's own immune system to maintain
overall health and well-being. They are sold in re-sealable
packages of 30 chews and are currently available in the United
States by ordering on-line at www.vivamunehealth.com.
About Oximunol(TM) Chewables - For
dogs
Oximunol(TM) Chewables are
scientifically-formulated chewable tablets that contain Avivagen's
proprietary, patented active ingredient OxC-beta. OxC-beta has been
shown to stimulate innate cellular immunity and may thereby help to
maintain overall health and well-being. Oximunol(TM) Chewables are
distributed by Bayer Healthcare LLC and are available through
veterinarians for dogs of all ages in the United States.
About OxC-beta for Livestock
OxC-beta for Livestock is available as a
10% pre-mix sold in 1.0 or 5.0 Kg quantities for parts-per-million
addition to animal feeds, in accordance with producer-developed
protocols. In past studies, OxC-beta has been shown to support
health and growth in species such as fish, chicken, pigs and
cattle. OxC-beta for livestock is currently
available for commercial sale in the Kingdom of
Thailand.
Forward Looking
Statements
Neither TSX
Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
For more
information:
Avivagen Inc.
Cameron Groome
CEO & President
Phone: 613-949-8164
c.groome@avivagen.com
Avivagen (TSXV:VIV)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Avivagen (TSXV:VIV)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024